Cocrystal Pharma, Inc. (COCP) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses.
Analysis Summary
Trailing-twelve-month margins: gross margin 205.8%, operating margin -30.6%, net margin -30.1%.
At the current price of $1.14, COCP has negative trailing earnings (P/E not meaningful) and an ROE of -207.47%. Market capitalisation stands at $16M.
Balance sheet quality for COCP: current ratio of 3.7, net cash position of $5.5M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $1.14 |
| Market Cap | $16M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 14.67 |
| EV / EBITDA | -1.55 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -207.47% |
| Return on Invested Capital | -423.90% |
| Return on Assets | -213.77% |
| Gross Margin | 205.76% |
| Operating Margin | -3063.64% |
| Net Margin | -3011.52% |
Financial Health
| Debt / Equity | 1.28 |
| Current Ratio | 1.24 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| COCP | Cocrystal Pharma, Inc. | $16M | 14.67 | -207.5% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.3B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $131.0B | 29.86 | 6.49 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.6B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $81.3B | 19.15 | 2.61 | 13.8% |
| MRNA | Moderna, Inc. | $62.7B | 1.46 | -39.2% | |
| ARGX | argenx SE | $61.9B | 36.71 | 7.48 | 21.7% |
| RVMD | Revolution Medicines, Inc. | $41.9B | 16.04 | -96.4% |
Price Performance
| 1 month | +5.56% |
| 3 months | +14.57% |
| Year-to-date | +16.45% |
| 1 year | -6.56% |
| 3 years | -43.84% |
| 5 years | -90.95% |
52-Week Range
| 52-week High | $2.03 |
| 52-week Low | $0.76 |
| Avg Volume (90d) | 78K |
Related companies: BOLT · BRTX · CING · DWTX · EVGN · IMNN · IMRN
Explore sector: Healthcare · Biotechnology
More sections of COCP: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks